News

CPhA today called on the Standing Committee on Health to consider both incremental and longer-term approaches to pan-Canadian pharmacare, including immediate steps to close the coverage gap.

CPhA appears before the House of Commons Standing Committee on Justice and Human Rights to both express its support for Bill C-14 and identify areas that require further work to fully address rights of conscience and access.

More than 700 pharmacists and pharmacy stakeholders will be in Calgary, Alberta from June 24-27 to discuss the key issues facing pharmacy in Canada and discover the latest in pharmacy practice research.

CPhA is pleased that the assisted dying legislation introduced today by the federal government appropriately recognizes the role of pharmacists and that specific protections and exemptions are in place.

To enhance public and patient safety in the rapidly evolving medical marijuana environment, CPhA is recommending that pharmacists play a front-line role in patient management and dispensing of medical marijuana.

CPhA is disappointed by Health Canada’s announcement to not move forward on regulations that would have required all controlled release oxycodone products to have tamper-resistant properties before they could be sold in Canada.

CPhA welcomes health care investments announced in the 2016 federal budget, particularly as they relate to e-prescribing and improving immunization coverage rates, and we look forward to working with the government on the implementation of these important initiatives.

CPhA welcomes the decision by Health Canada to revise the federal prescription status of naloxone, a medication that has the potential to significantly reduce the frequency of deaths that occur with opioid overdosage.